Drug Profile

Azithromycin/hydroxychloroquine - Iterum Therapeutics

Alternative Names: Azithromycin plus hydroxychloroquine; Azithromycin/hydroxychloroquine

Latest Information Update: 28 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Iterum Therapeutics
Class Anti-inflammatories; Antibacterials; Antimalarials; Antivirals; Chlorobenzenes; Disease-modifying antirheumatics; Ethanolamines; Macrolides; Quinolines; Small molecules
Mechanism of Action Autophagy inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Sep 2025 No recent reports of development identified for preclinical development in Respiratory-tract-infections in USA (PO)
09 Sep 2021 Chemical structure information added
07 Sep 2021 Iterum Therapeutics plans a phase III trial for Respiratory tract infections in USA (PO) in October 2021 (NCT05026801)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com